Status:

COMPLETED

Surveillance for Leishmaniasis Skin Lesions in Mali

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Cutaneous Leishmaniasis

Eligibility:

All Genders

1+ years

Brief Summary

This study will examine why some people who become infected with the leishmaniasis parasite develop skin lesions and others do not. The parasite that causes leishmaniasis is transmitted by the bite of...

Detailed Description

The overarching aim of the research program is to develop a vaccine against cutaneous leishmaniasis (CL) based on sandfly salivary proteins (SFSPs). In order to determine whether vaccination with SFSP...

Eligibility Criteria

Inclusion

  • ELIGIBILITY CRITERIA:
  • Only consented volunteers who are permanent residents of Kemena or Sougoula, and who do not have known sensitivity to thiomerosal, will be invited to participate in this study. Otherwise, inclusion criteria specific for each phase of this study are as follows:
  • Administration of LST, April-May 2006:
  • Age greater than or equal to 1
  • Active and passive detection of CL, August-December 2006:
  • LST negative status in April 2006.
  • Aspiration of CL lesions, August-December 2006:
  • Age greater than or equal to18 years, AND
  • Presence of one or more clinically diagnosed CL lesion
  • Re-administration of LST in February-March 2007:
  • LST negative status in April 2006
  • Collection of whole blood for immunological studies, May 2007 - May 2008:
  • Age greater than or equal to 3 years and less than or equal to 65 years, AND
  • LST negative status in February-March 2007.
  • Active detection of CL, May 2007- May 2008:
  • LST negative status in February-March 2007.
  • Aspiration of CL lesions, May 2007 - May 2008:
  • Age greater than or equal to 3 years, AND
  • Presence of at least one PCR-diagnosed CL lesion.
  • Collection of fingerprick blood sample, January-March 2008:
  • Currently or previously enrolled on protocol
  • Re-administration of LST, June-July 2008:
  • LST negative status in February-March 2007.
  • Collection of whole blood for immunological studies, June - August 2008:
  • Age greater than or equal to 3 years and less than or equal to 65 years, AND
  • LST negative status in February-March 2007, AND
  • One of the following:
  • Conversion from negative to positive LST reaction during the study period, OR
  • Occurrence of greater than or equal to 1 PCR-confirmed CL lesion during 10-month survey period, regardless of June-July 2008 LST result, OR
  • Repeat LST negative result and absence of PCR-confirmed CL lesion during 10-month surveillance period.
  • Collection of whole blood from healthy volunteers naturally exposed to P. duboscqi October 2008-October 2012
  • Aqe greater than or equal to 11 years and less than or equal to 65 years, AND resident of Kemena or Sougoula OR patient with a Giemsa stain-confirmed CL lesion beinq evaluated and treated bY study physicians at CNAM in Bamako.
  • Exposure of individuals to the bites of laboratory-reared, noninfected P. duboscai October 2008-October 2012
  • Age greater than or equal to 1 years and less than or equal to 65 years AND resident of Kemena or Souaoula.
  • Dermal biopsy of DTH reactions occurring in individuals exposed to the bites of laboratory-reared, noninfected P. duboscai October 2008- October 2012
  • Age 18-65 years AND resident of Kemena or Souqoula.

Exclusion

    Key Trial Info

    Start Date :

    March 16 2006

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    September 17 2012

    Estimated Enrollment :

    1593 Patients enrolled

    Trial Details

    Trial ID

    NCT00344084

    Start Date

    March 16 2006

    End Date

    September 17 2012

    Last Update

    November 8 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Faculty of Medicine Pharmacy and Dentistry

    Bamako, Mali